📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 13:17
8 analysed today
FollowTelegram
8
Today
149,959
All-time analysed
42,990
Positive
6,669
Negative
91,590
Neutral
8,642
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Brawn Biotech Q1 Revenue Drops 85% YoY to ₹0.83 Cr; Net Profit at ₹0.16 Cr
Brawn Biotech reported a significant contraction in its top-line for Q1 FY27, with revenue from operations falling 85.7% YoY to ₹0.83 Cr from ₹5.80 Cr. Despite the sharp revenue decline, the company remained profitable with a net profit of ₹0.16 Cr, though this was down 33.3% from ₹0.24 Cr in the year-ago period. The company has also proposed the appointment of M/s GD S M and Co as new statutory auditors for a five-year term. The results reflect a micro-cap company (₹6 Cr market cap) struggling to maintain its previous scale of operations.
Confidence: HIGH
What changedThe company experienced a massive reduction in business scale during the quarter and is transitioning to a new statutory auditor.
Why it mattersFor a company with a ₹6 Cr market cap, a quarterly revenue of just ₹0.83 Cr (compared to a TTM average of ~₹4.25 Cr per quarter) indicates a severe operational slowdown or loss of major business segments.
Revenue from Operations (Q1): ₹0.83 CrYoY Revenue Growth: -85.7%Net Profit (Q1): ₹0.16 CrQ1 Revenue vs TTM Revenue: 4.88%EPS (Q1): ₹0.52
📅 Short termThe stock is likely to react negatively to the sharp decline in revenue, although the maintenance of profitability provides a small cushion.
📈 Long termThe long-term outlook is highly uncertain given the volatility in revenue; the company needs to demonstrate a return to its FY26 revenue levels (₹16.98 Cr) to sustain investor interest.
⚠ Risk flags
- Severe revenue contraction
- Micro-cap liquidity risk
- Change in statutory auditors
- High volatility in quarterly performance
Key Highlights
Revenue from operations plummeted to ₹0.83 Cr in Q1 FY27 from ₹5.80 Cr in Q1 FY26.
Net profit for the quarter stood at ₹0.16 Cr, a decline from ₹0.24 Cr YoY.
Basic Earnings Per Share (EPS) decreased to ₹0.52 from ₹0.80 in the corresponding quarter last year.
Total expenses were drastically reduced to ₹0.81 Cr from ₹5.55 Cr, primarily due to lower purchase of stock-in-trade.
Board recommended the appointment of M/s GD S M and Co as Statutory Auditors for a 5-year term starting from the upcoming AGM.
👀 What to Watch
Investors should monitor the upcoming Annual General Meeting on September 29, 2026, for management's explanation regarding the 85% revenue drop and their plan to restore business volume.
Brawn Biotech Q1 FY27: Revenue Plummets 86% YoY to ₹0.82 Cr; PAT at ₹0.04 Cr
Brawn Biotech reported a severe contraction in its financial performance for the quarter ended June 30, 2026. Revenue from operations fell to ₹0.82 Cr, an 85.8% decline from ₹5.80 Cr in the same quarter last year. Net profit followed suit, dropping 83.3% YoY to just ₹0.04 Cr. Additionally, the board has recommended the appointment of M/s G D S M and Co as new statutory auditors for a five-year term, pending shareholder approval at the upcoming AGM on September 29, 2026.
Confidence: HIGH
What changedThe company experienced a significant scale-down in operations during Q1 FY27 and is transitioning to a new statutory auditor.
Why it mattersFor a micro-cap company with a ₹6 Cr market cap, an 86% drop in revenue is highly material and suggests extreme volatility or the loss of major clients/contracts.
Q1 Revenue from Operations: ₹0.82 CrYoY Revenue Growth: -85.8%Q1 Net Profit: ₹0.04 CrQ1 EPS: ₹0.13Revenue vs TTM Revenue: ~4.8%
📅 Short termThe stock is likely to face negative pressure due to the substantial decline in both top-line and bottom-line performance.
📈 Long termThe structural outlook is uncertain; the company must demonstrate its ability to regain its previous quarterly revenue run-rate of ₹4-5 Cr to remain viable.
⚠ Risk flags
- Severe revenue contraction
- Micro-cap liquidity risk
- Auditor change
- High volatility in quarterly earnings
Key Highlights
Revenue from operations declined sharply to ₹0.82 Cr from ₹5.80 Cr in June 2025.
Net profit for the quarter stood at ₹0.04 Cr, down from ₹0.24 Cr in the year-ago period.
Total expenses were curtailed to ₹0.86 Cr, down from ₹5.65 Cr YoY, primarily due to lower purchase of stock-in-trade.
The board recommended a new statutory auditor, M/s G D S M and Co, for a 5-year tenure (2026-2031).
The 41st Annual General Meeting (AGM) is scheduled for September 29, 2026, via video conferencing.
👀 What to Watch
Investors should monitor the upcoming AGM for management commentary regarding the cause of the massive revenue drop and whether this represents a permanent loss of business or a temporary cyclical delay.
